NCT01783587 2026-03-25
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
95 trialsNCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
NCT01856478 2026-01-12
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed
NCT07271446 2025-12-09
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Precision Biotech Taiwan Corp.
Phase 1 Completed
NCT00716417 2025-08-05
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT05517330 2025-07-31
neoCHANCE-1
West China Hospital
Phase 2 Completed
NCT02191891 2025-06-25
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 1 Completed
NCT05516589 2025-05-22
neoCHANCE-2
West China Hospital
Phase 2 Completed
NCT01853826 2025-04-11
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Boehringer Ingelheim
Phase 3 Completed
NCT05298176 2025-03-28
COMBINATION
Amsterdam UMC, location VUmc
Phase 2 Completed
NCT02597946 2025-02-19
Afatinib in NSCLC With HER2 Mutation
Boehringer Ingelheim
Phase 2 Completed
NCT03083678 2025-02-13
Afatinib in Locally Advanced and Metastatic Chordoma
Leiden University Medical Center
Phase 2 Completed
NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT00950742 2025-02-10
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT01214616 2025-02-07
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02171650 2025-01-23
BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02364609 2024-10-16
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
University of California, Davis
Phase 1 Completed
NCT04839471 2024-07-08
BEAR
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT04410653 2024-04-05
Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
Phase 2 Completed
NCT01542437 2024-02-06
NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02183883 2023-11-29
DARWIN1
University College, London
Phase 2 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03727724 2023-10-18
AFACET
The Netherlands Cancer Institute
Phase 2 Completed
NCT02506517 2023-08-01
A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
University Health Network, Toronto
Phase 2 Completed
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT04201756 2022-12-23
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Completed
NCT02716311 2022-08-11
ACE-Lung
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT02451553 2022-06-07
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
Phase 1 Completed
NCT03695510 2022-04-21
ALPHA
National Taiwan University Hospital
Phase 2 Completed
NCT01156545 2022-04-06
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
National Cancer Center, Korea
Phase 2 Completed
NCT02423525 2022-03-10
Safety Study of Afatinib for Brain Cancer
Saint John's Cancer Institute
Phase 1 Completed
NCT01415674 2022-02-02
PREDICTOR
UNICANCER
Phase 2 Completed
NCT02629523 2021-08-03
LiquidLung-A
Chonnam National University Hospital
Phase 2 Completed
NCT01427478 2021-06-01
BIBW2992ORL
Centre Leon Berard
Phase 3 Completed
NCT02747953 2021-03-19
Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
Samsung Medical Center
Phase 2 Completed
NCT02372006 2021-03-04
Trial of Afatinib in Pediatric Tumours
Boehringer Ingelheim
Phase 1/2 Completed
NCT03157089 2021-02-23
LUX-Lung-IO
Boehringer Ingelheim
Phase 2 Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02780687 2020-11-18
LUX-Bladder 1
Boehringer Ingelheim
Phase 2 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT02514174 2020-03-30
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Boehringer Ingelheim
Phase 4 Completed
NCT01953913 2019-08-12
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed
NCT01125566 2019-07-18
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim
Phase 3 Completed
NCT01271725 2019-06-17
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
Phase 2 Completed
NCT02145637 2019-03-29
Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
Yonsei University
Phase 1 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT01523587 2019-02-15
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed